Literature DB >> 12027986

Percutaneous radiofrequency thermoablation as an alternative to surgery for treatment of liver tumour recurrence after hepatectomy.

D Elias1, T De Baere, T Smayra, J F Ouellet, A Roche, P Lasser.   

Abstract

BACKGROUND: Radiofrequency (RF) current, converted into heat through ion agitation and friction, can destroy liver tumours by means of coagulation necrosis. This study assessed whether percutaneous RF ablation is a useful and safe technique for the treatment of liver tumour recurrence after hepatectomy.
METHODS: Forty-seven patients presenting with local recurrence after hepatectomy for malignant tumours (29 with colorectal secondaries) were treated with percutaneous RF ablation instead of repeat hepatectomy. RF thermal ablation was performed under image guidance for 12-15 min. This group represented 63 per cent of 75 patients treated with curative intent for liver recurrence in the same time interval. The other 28 patients underwent repeat hepatectomy.
RESULTS: The mean(s.d.) number of liver metastases destroyed was 1.4(0.7) (range 1-3) and their diameter was 21(8) (range 9-35) mm. Twenty-six patients presented with liver recurrence at least once but up to three times after the initial RF application. Incomplete local RF treatment was observed in six of 47 patients. Fifteen patients developed extrahepatic recurrence. The mean(s.d.) interval between RF ablation and the last follow-up visit was 14.4(10.1) (range 5.5-40) months. One death and three major complications occurred. Survival rates at 1 and 2 years were 88 and 55 per cent respectively. A retrospective study of the authors' database over two similar consecutive periods showed that RF ablation increased the percentage of curative local treatments for liver recurrence after hepatectomy from 17 to 26 per cent and decreased the proportion of repeat hepatectomies from 100 to to 39 per cent.
CONCLUSION: Percutaneous RF treatment increases the number of patients eligible for curative treatment. It should be preferred to repeat hepatectomy when feasible and safe because it is less invasive. Repeat hepatectomy is indicated only when percutaneous RF ablation is contraindicated or fails.

Entities:  

Mesh:

Year:  2002        PMID: 12027986     DOI: 10.1046/j.1365-2168.2002.02081.x

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  26 in total

Review 1.  Radiofrequency thermal ablation of liver tumors.

Authors:  Elisabetta Buscarini; Agostino Savoia; Gianfranco Brambilla; Fernanda Menozzi; Luigi Reduzzi; Deike Strobel; Johannes Hänsler; Luigi Buscarini; Luigi Gaiti; Alessandro Zambelli
Journal:  Eur Radiol       Date:  2005-03-08       Impact factor: 5.315

2.  Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases.

Authors:  Xiaodong Wang; Constantinos T Sofocleous; Joseph P Erinjeri; Elena N Petre; Mithat Gonen; Kinh G Do; Karen T Brown; Anne M Covey; Lynn A Brody; William Alago; Raymond H Thornton; Nancy E Kemeny; Stephen B Solomon
Journal:  Cardiovasc Intervent Radiol       Date:  2012-04-26       Impact factor: 2.740

Review 3.  Thermal Ablation in the Management of Colorectal Cancer Patients with Oligometastatic Liver Disease.

Authors:  Elena Nadia Petre; Constantinos Sofocleous
Journal:  Visc Med       Date:  2017-02-03

Review 4.  Image guided tumour ablation.

Authors:  A R Gillams
Journal:  Cancer Imaging       Date:  2005-09-21       Impact factor: 3.909

5.  Percutaneous ablation of post-surgical solitary early recurrence of colorectal liver metastases is an effective "test-of-time" approach.

Authors:  Luca Vigano; Jacopo Galvanin; Dario Poretti; Daniele Del Fabbro; Damiano Gentile; Vittorio Pedicini; Luigi Solbiati; Guido Torzilli
Journal:  Updates Surg       Date:  2021-04-12

6.  Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence.

Authors:  Kosuke Mima; Toru Beppu; Akira Chikamoto; Yuji Miyamoto; Shigeki Nakagawa; Hideyuki Kuroki; Hirohisa Okabe; Hiromitsu Hayashi; Yasuo Sakamoto; Masayuki Watanabe; Ken Kikuchi; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2012-09-01       Impact factor: 3.402

7.  Development of a research agenda for the management of metastatic colorectal cancer: proceedings from a multidisciplinary research consensus panel.

Authors:  Bertrand Janne d'Othée; Constantinos T Sofocleous; Nader Hanna; Robert J Lewandowski; Michael C Soulen; Jean-Nicolas Vauthey; Steven J Cohen; Alan P Venook; Matthew S Johnson; Andrew S Kennedy; Ravi Murthy; Jean-Francois Geschwind; Stephen T Kee
Journal:  J Vasc Interv Radiol       Date:  2012-02       Impact factor: 3.464

8.  Long-term survival of patients with unresectable colorectal liver metastases treated by percutaneous interstitial laser thermotherapy.

Authors:  Christopher Christophi; Mehrdad Nikfarjam; Caterina Malcontenti-Wilson; Vijayaragavan Muralidharan
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

9.  Repeat liver resection for recurrent colorectal metastases: a single-centre, 13-year experience.

Authors:  Narendra Battula; Dimitrios Tsapralis; David Mayer; John Isaac; Paolo Muiesan; Robert P Sutcliffe; Simon Bramhall; Darius Mirza; Ravi Marudanayagam
Journal:  HPB (Oxford)       Date:  2013-03-27       Impact factor: 3.647

10.  Practical questions in liver metastases of colorectal cancer: general principles of treatment.

Authors:  Héctor Daniel González; Joan Figueras
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.